Results Published from Trial of Siponimod in Secondary Progressive MS

Thursday, April 12, 2018

The Lancet recently published an article demonstrating the efficacy of a new MS medication, Siponimod, in secondary progressive MS patients. Siponimod is very similar to a currently available medication, called fingolimod or gilenya, but may have a better safety profile. The results of the study were modest and research on this drug is ongoing. 

 

To read more about the published article please click here

News Archive

Pages

Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy

 

Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.